Full history for every metric is available with a Kvantra account
ImmunoGen, Inc. (IMGN)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 115 | 54 | 82 | 132 | 70 | 109 | 288 |
| Operating profit | $m | -221 | -80 | |||||
| Net profit | $m | -96 | -168 | -122 | -67 | -139 | -223 | -73 |
| EPS reported | $ | -0.88 | -0.31 | |||||
| Operating cashflow per share | $ | -0.91 | -0.91 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -0.91 | -0.91 | |||||
| Free cash flow | $m | -231 | -200 | |||||
| Net debt | $m | -260 | -541 | |||||
| Book value equity | $m | 156 | 562 | |||||
| Book value per share | $ | 0.61 | 1.95 | |||||
| Number of shares | m | 253.63 | 287.59 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 8.07 | 15.54 | |||||
| P/S LTM | x | 11.56 | 30.34 | |||||
| P/FCF LTM | x | -5.44 | -43.68 | |||||
| EV/EBITDA LTM | x | -4.63 | -130.30 | |||||
| EV/Sales LTM | x | 9.18 | 28.46 | |||||
| Earnings Yield LTM | % | -17.72% | -2.81% | |||||
| FCF Yield | % | -18.38% | -2.29% | |||||
| Quality | ||||||||
| ROE | % | -143.06% | -92.61% | |||||
| ROIC | % | -95.55% | -95.55% | |||||
| Operating margin | % | -203.06% | -203.06% | |||||
| Gross margin | % | 99.84% | 99.84% | |||||
| FCF/Sales | % | -212.50% | -212.50% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +55.72% | +200.83% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -15.16 | -2.77 | |||||
| Net Debt/EBITDA | x | 1.20 | 1.20 | |||||
| EBIT/Net interest | x | -53.04 | -53.04 | |||||
| Net debt/market cap | % | -20.66% | -6.20% | |||||
| Net debt/Equity | x | -1.67 | -0.96 | |||||
| Gross debt/equity | x | 0.10 | 0.13 | |||||
Company overview
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer. Another significant candidate, Pivekimab sunirine, a CD123-targeting ADC, is progressing through Phase II studies for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Beyond its clinical efforts, the company's preclinical portfolio includes IMGC936, an ADC being co-developed with MacroGenics, Inc., and IMGN151, another anti-FRa therapeutic. ImmunoGen maintains strategic collaborations with a range of key industry players, such as Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. Founded in 1980, ImmunoGen, Inc. is headquartered in Waltham, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
ImmunoGen, Inc. (IMGN)
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer. Another significant candidate, Pivekimab sunirine, a CD123-targeting ADC, is progressing through Phase II studies for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Beyond its clinical efforts, the company's preclinical portfolio includes IMGC936, an ADC being co-developed with MacroGenics, Inc., and IMGN151, another anti-FRa therapeutic. ImmunoGen maintains strategic collaborations with a range of key industry players, such as Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. Founded in 1980, ImmunoGen, Inc. is headquartered in Waltham, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free